drugset / Trial / NCT00924807
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be administered at the same time as standard treatment, which includes hormonal therapy and external beam radiotherapy.
Timeline
- Start
- 2008-09
- Primary completion
- 2013-12
- Completion
- 2013-12
Outcome
Outcome not reported
Stopped: “Sponsor closed the trial”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | — |
| Background | Bicalutamide | Other / unclassified | 50 mg | — |
| Background | Leuprolide | Other / unclassified | — | — |